You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Proprietary drug to treat radiodermatitis

    SBC: Allander Biotechnologies            Topic: NIAMS

    Summary Radiodermatitis is skin tissue damage that occurs in 95% of cancer patients receiving radiotherapy (RT). Although modern RT, e.g., intensity-modulated RT (IMRT) or stereotactic body RT (SBRT), spares more skin areas from RT damage than regular RT, radiodermatitis is still the major toxicity in skin cancer patients treated with SBRT as well as in other cancer patients treated with regular R ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer

    SBC: Aurora Oncology, Inc.            Topic: 399

    Project Summary/Abstract Bladder cancer causes over 165,000 annual deaths worldwide with 70,000 new cases and 16,000 deaths reported in the US. Treatment of superficial bladder cancer by resection and BCG administration is unsuccessful in 40% of cases with recurrences eventually requiring cystectomy or other aggressive therapy; new therapies are needed. The role of Epidermal Growth Factor Receptor ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: OD

    Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with a predicted incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The 7β1 integrin is a transmembrane linkage system in skeleta ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Automated, high-throughput identification of genetic structural variants for gene editing and undiagnosed genetic diseases screening

    SBC: KromaTiD, Inc.            Topic: 172

    ABSTRACT A simple method to comprehensively discover, characterize and identify structural variants arising from normal metabolic processes, as well as cell manipulations, would have great utility for gene editing, oncology, and rare disease research, among other applications. De Novo Directional Genomic Hybridization (dGH™) has been developed to efficiently screen thousands of cells for the pre ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. A ratcheting prosthetic partial finger using advanced rapid manufacturing technology

    SBC: POINT DESIGNS, LLC            Topic: NICHD

    A Ratcheting Prosthetic Partial Finger Using AdvancedRapid Manufacturing Technology Project Summary / Abstract The goal of the proposed project is to develop and commercialize a purely mechanical, ratcheting prosthetic partial finger – the Point Partial – which 1) has an industry leading strength to weight ratio, 2) can be operated unilaterally, 3) offers anatomical rotation and flexion around ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. High-resolution Non-cryogenic Magnetoencephalography: Systems-Level Integration

    SBC: QUSPIN INC.            Topic: 105

    Abstract Magnetoencephalography (MEG) is an important functional neuroimaging technique that provides an excellent combination of high spatial and temporal resolution. At present, MEG scanners are handicapped by cost and complexity imposed by cryogenically cooled superconducting sensor technology. In our recently completed Phase II project, we developed new noncryogenic optical sensors that are su ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Enabling self-reported outcomes for youth with developmental disabilities: The PediatricEvaluation of Disability Inventory- Patient Reported Outcome (PEDI-PRO)- Phase II

    SBC: ABLELINK TECHNOLOGIES INC            Topic: NICHD

    The lack of patient reported outcome measures (PROMs) appropriate for youth with neurodevelopmental disabilities (DD) and related cognitive impairments including Down syndrome (DS) poses a significant problem for healthcare research and practice. Parents and other professionals do not identify the same needs as youth, and failure to engage youth with DD in healthcare evaluation compromises healthc ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Stage-Based Mobile Intervention for Substance Use Disorders in Primary Care: Implementation and Cluster-Randomized Trial

    SBC: Pro-Change Behavior Systems Inc            Topic: NIDA

    Nearly 22 million Americans age 12 and older (8.1%) need treatment for a substance use disorder (SUD). While only 10%-11% of individuals requiring treatment for a SUD receive it, an estimated two-thirds see a primary care or urgent care provider every 6 months. Primary care providers are in a unique position to perform Screening, Brief Intervention, and Referral to Treatment (SBIRT). With Phase I ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. BMX-001 as a Therapeutic Agent for Treatment of High-Grade Gliomas

    SBC: BIOMIMETIX JV LLC            Topic: NCI

    PROJECT SUMMARY/ABSTRACT A randomized, proof-of-concept, Phase 2 clinical trial of a new class of redox-active pharmaceutical is proposed in 160 subjects undergoing primary treatment for high-grade glioma (WHO grade III and IV). Under a prior Phase II SBIR, a Phase 1 clinical trial has been completed with establishment of the recommended dose being used for this Phase 2 clinical trial. This projec ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Enhancing the Commercialization Readiness of a Noninvasive Total Hemoglobin Monitor

    SBC: Kestrel Labs Inc            Topic: NHLBI

    Abstract It is a rare event when new and useful medical parameters can be added to the suite of monitoring and diagnostic tests available in a clinical setting. Of particular importance is the ability to measure crucial physiological parameters or analytes in a continuous and noninvasive manner—evidenced by the importance of noninvasive vital signs monitoring—because it reduces expense, elimin ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government